Evidence map›Paper›PMID 34935124›Full record

ArticleBiotechnology and bioengineering2022

Loss of a newly discovered microRNA in Chinese hamster ovary cells leads to upregulation of N-glycolylneuraminic acid sialylation on monoclonal antibodies.

Simon Fischer, Sven Mathias, Anna Stadermann, Shumin Yang, Valerie Schmieder, Nikolas Zeh, Nicoletta Schmidt, Patrick Richter, Sara Wright, Eike Zimmermann and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. CRISPR Technologies in Chinese Hamster Ovary Cell Line Engineering.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Simon FischerCell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.ORCID 0000-0002-5188-7620
Sven MathiasEarly Stage Bioprocess Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.ORCID 0000-0002-2842-8549
Anna StadermannCell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Shumin YangProcess Science, Boehringer Ingelheim Fremont Inc., Fremont, California, USA.
Valerie SchmiederCell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Nikolas ZehCell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Nicoletta SchmidtCell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Patrick RichterCell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Sara WrightAnalytical Science, Boehringer Ingelheim Fremont Inc., Fremont, California, USA.
Eike ZimmermannAnalytical Science, Boehringer Ingelheim Fremont Inc., Fremont, California, USA.
Yan LeyAnalytical Science, Boehringer Ingelheim Fremont Inc., Fremont, California, USA.
Julia van der MeerGenedata AG, Basel, Switzerland.
Thomas HartschGenedata AG, Basel, Switzerland.
Christian BernloehrEarly Stage Bioprocess Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Kerstin OtteInstitute of Applied Biotechnology, University of Applied Sciences, Biberach, Germany.
Harald BradlProtein Science, Bioprocess & Analytical Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Martin GamerCell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Patrick SchulzCell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Boehringer Ingelheim (Germany) · DEBoehringer Ingelheim (United States) · USGenedata (Switzerland) · CHUniversity of Applied Sciences Biberach · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chinese hamster ovary (CHO) cells are known not to express appreciable levels of the sialic acid residue N-glycolylneuraminic acid (NGNA) on monoclonal antibodies. However, we actually have identified a recombinant CHO cell line expressing an IgG with unusually high levels of NGNA sialylation (>30%). Comprehensive multi-OMICs based experimental analyses unraveled the root cause of this atypical sialylation: (1) expression of the cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) gene was spontaneously switched on, (2) CMAH mRNA showed an anti-correlated expression to the newly discovered Cricetulus griseus (cgr) specific microRNA cgr-miR-111 and exhibits two putative miR-111 binding sites, (3) miR-111 expression depends on the transcription of its host gene SDK1, and (4) a single point mutation within the promoter region of the sidekick cell adhesion molecule 1 (SDK1) gene generated a binding site for the transcriptional repressor histone H4 transcription factor HINF-P. The resulting transcriptional repression of SDK1 led to a downregulation of its co-expressed miR-111 and hence to a spontaneous upregulation of CMAH expression finally increasing NGNA protein sialylation.

Indexed as

Antibodies, MonoclonalMicroRNAsAnimalsCHO CellsCricetinaeCricetulusN-Acetylneuraminic AcidNeuraminic AcidsRecombinant ProteinsUp-RegulationAntibodies, MonoclonalMicroRNAsN-Acetylneuraminic AcidNeuraminic AcidsN-glycolylneuraminic acidRecombinant ProteinsChinese hamster ovary (CHO) cellsmicroRNAmonoclonal antibodyN-glycosylationsialylation

Identifiers

PMID34935124
PMCPMC9306616
OpenAlexW4200291881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.